Last reviewed · How we verify
Pralidoxime Chloride (Autoinjector) (PRALIDOXIME)
Pralidoxime Chloride works by reactivating the enzyme acetylcholinesterase, which is inhibited by organophosphate poisoning.
Pralidoxime Chloride (Autoinjector) (PRALIDOXIME) is a cholinesterase reactivator developed by Baxter Healthcare Corp. It targets acetylcholinesterase to treat cholinesterase inhibitors toxicity, organophosphate poisoning, and organophosphorous overdose. Originally approved by the FDA in 1964, it remains off-patent with no active Orange Book patents. The autoinjector modality provides a convenient treatment option for emergency situations. Key safety considerations include its short half-life of 1.4 hours.
At a glance
| Generic name | PRALIDOXIME |
|---|---|
| Sponsor | Baxter |
| Drug class | Cholinesterase Reactivator |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1964 |
Mechanism of action
Imagine your body's 'off' switch for a chemical called acetylcholine. When you're poisoned with something like nerve gas, this switch gets stuck in the 'on' position, causing problems. Pralidoxime Chloride helps flip the switch back to 'off' by reactivating the enzyme that normally turns it off.
Approved indications
- Cholinesterase Inhibitors Toxicity
- Organophosphate poisoning
- Organophosphorous Overdose
- Poisoning due to Nerve Agent
Common side effects
- Muscular weakness
- Elevations in SGOT and/or SGPT enzyme levels
- Transient elevations in creatine phosphokinase
- Dizziness
- Headache
- Drowsiness
- Nausea
- Tachycardia
- Increased systolic and diastolic blood pressure
- Hyperventilation
- Blurred vision
- Diplopia
Key clinical trials
- Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime (PHASE2)
- Serum Cholinesterase Level in Aluminum Phosphide Poisoning, the Possible Proposing Role of Atropin & Pralidoxime
- Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning (PHASE3)
- Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning? (PHASE1)
- Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |